TSRO - TESARO Stock Price, News & Analysis

$83.91 -1.19 (-1.40 %)
(As of 11/24/2017 02:40 AM ET)
Previous Close$85.10
Today's Range$83.41 - $86.02
52-Week Range$83.35 - $192.94
Volume708,300 shs
Average Volume1.03 million shs
Market Capitalization$4.63 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.64

About TESARO (NASDAQ:TSRO)

TESARO logoTESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. Rolapitant is a potent and long-acting neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Niraparib is an orally active and potent poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitor. It has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers. It has initiated a Phase I, dose escalation study for its first immuno-oncology antibody, TSR-042, which targets Programmed cell death protein 1. It has commenced pre-clinical research for its antibody candidate targeting Lymphocyte-activation gene-3 andTSR-033. It has commenced a Phase I clinical trial of TSR-042.


Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:TSRO
CUSIP88156910

Debt

Debt-to-Equity Ratio0.34%
Current Ratio4.73%
Quick Ratio4.35%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$44.82 million
Price / Sales101.81
Cash FlowN/A
Price / CashN/A
Book Value$7.49 per share
Price / Book11.20

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS($8.44)
Net Income$-387,470,000.00
Net Margins-251.22%
Return on Equity-93.39%
Return on Assets-61.53%

Miscellaneous

Employees446
Outstanding Shares54,380,000

Frequently Asked Questions for TESARO (NASDAQ:TSRO)

What is TESARO's stock symbol?

TESARO trades on the NASDAQ under the ticker symbol "TSRO."

How were TESARO's earnings last quarter?

TESARO, Inc. (NASDAQ:TSRO) issued its quarterly earnings results on Tuesday, November, 7th. The biopharmaceutical company reported ($0.47) EPS for the quarter, topping analysts' consensus estimates of ($1.16) by $0.69. The biopharmaceutical company earned $142.77 million during the quarter, compared to analyst estimates of $130.57 million. TESARO had a negative return on equity of 93.39% and a negative net margin of 251.22%. The company's quarterly revenue was up 740.3% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.72) earnings per share. View TESARO's Earnings History.

Where is TESARO's stock going? Where will TESARO's stock price be in 2017?

23 brokers have issued 1 year price targets for TESARO's shares. Their predictions range from $117.00 to $236.00. On average, they anticipate TESARO's share price to reach $161.00 in the next year. View Analyst Ratings for TESARO.

What are Wall Street analysts saying about TESARO stock?

Here are some recent quotes from research analysts about TESARO stock:

  • 1. According to Zacks Investment Research, "Tesaro, Inc. is an oncology-focused biopharmaceutical company for cancer patients. The Company's product portfolio consists of Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting, TSR-011, an orally available anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer and other cancer indications, and Niraparib, an orally active and potent poly (ADP-ribose) polymerase inhibitor for the treatment of patients with solid tumors. Tesaro, Inc. is based in Waltham, Massachusetts. " (11/8/2017)
  • 2. Cann analysts commented, "Total Q3 revenue of $142.8 million included a $100 million upfront payment. Net of the upfront payment, revenue was 27.4% higher than our estimated $33.6 million due to stronger than estimated Zejula sales. Total operating expenses of $164.9 million were 3.0% lower than our estimated $170.0 million due to lower than estimated R&D expense. Due to the combination of higher than estimated revenue and slightly lower expenses, Tesaro lost $0.47 per share compared to our estimated loss per share of $2.56." (11/7/2017)
  • 3. FBR & Co analysts commented, "We received our first data snapshot from the RX-3117 Phase 2a study in advanced muscle invasive bladder cancer at ASCO this weekend with data coming from 10 patients in stage 1 of the study. The study achieved the predefined efficacy criteria (two of ten patients achieving a PFS of at least four months or a partial or complete tumor response), where 22% of patients have experienced PFS for a minimum of six months. One of the two aforementioned patients is still on study, achieving 175 days of stable disease. While only stage 1 of this study, we believe it is important to point out that patients who have reached this stage of disease are usually limited to palliative or best supportive care." (6/5/2017)
  • 4. Cowen Inc analysts commented, "TSRO reported 1Q financials, provided a pipeline update and commented on Zejula’s." (5/11/2017)
  • 5. Wedbush analysts commented, "With first-mover advantage in the maintenance setting, a lack of requirement for a diagnostic, as well clinical data that is at least as good as Lynparza in gBRCA patients, we continue to believe that TSRO remains an attractive acquisition candidate." (3/28/2017)

Who are some of TESARO's key competitors?

Who are TESARO's key executives?

TESARO's management team includes the folowing people:

  • David M. Mott, Independent Chairman of the Board (Age 51)
  • Mary Lynne Hedley Ph.D., President, Chief Operating Officer, Director (Age 54)
  • Leon O. Moulder Jr., Chief Executive Officer, Director (Age 59)
  • Timothy R. Pearson, Chief Financial Officer, Executive Vice President, Principal Accounting Officer (Age 49)
  • Jeffrey H. Hanke Ph.D., Executive Vice President - Research and Development, Chief Scientific Officer (Age 59)
  • Joseph L. Farmer, Senior Vice President, General Counsel, Secretary (Age 45)
  • Grant C. Bogle, Senior Vice President, Chief Commercial Officer (Age 59)
  • Martin H. Huber M.D., Senior Vice President and Chief Medical Officer (Age 57)
  • Edward C. English, Chief Accounting Officer
  • Lawrence M. Alleva, Independent Director (Age 67)

Who owns TESARO stock?

TESARO's stock is owned by many different of institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (1.65%), Pictet Asset Management Ltd. (1.16%), Bank of New York Mellon Corp (1.05%), Alyeska Investment Group L.P. (0.75%), Perceptive Advisors LLC (0.71%) and Jennison Associates LLC (0.62%). Company insiders that own TESARO stock include Arnold L Oronsky, Edward C English, Enterprise Associates 13 L New, Grant C Bogle, James O Armitage, Jeffrey H Hanke, Martin H Jr Huber, Mary Lynne Hedley and Orlando Oliveira. View Institutional Ownership Trends for TESARO.

Who sold TESARO stock? Who is selling TESARO stock?

TESARO's stock was sold by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., Bank of New York Mellon Corp, Macquarie Group Ltd., Schwab Charles Investment Management Inc., C WorldWide Group Holding A S, First Trust Advisors LP, TD Asset Management Inc. and State of Wisconsin Investment Board. Company insiders that have sold TESARO company stock in the last year include Edward C English, Grant C Bogle, James O Armitage, Martin H Jr Huber, Mary Lynne Hedley and Orlando Oliveira. View Insider Buying and Selling for TESARO.

Who bought TESARO stock? Who is buying TESARO stock?

TESARO's stock was acquired by a variety of institutional investors in the last quarter, including TimesSquare Capital Management LLC, Pictet Asset Management Ltd., Janus Henderson Group PLC, Sectoral Asset Management Inc, Artisan Partners Limited Partnership, Candriam Luxembourg S.C.A., Alyeska Investment Group L.P. and Prudential Financial Inc.. Company insiders that have bought TESARO stock in the last two years include Arnold L Oronsky and Enterprise Associates 13 L New. View Insider Buying and Selling for TESARO.

How do I buy TESARO stock?

Shares of TESARO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is TESARO's stock price today?

One share of TESARO stock can currently be purchased for approximately $83.91.

How big of a company is TESARO?

TESARO has a market capitalization of $4.63 billion and generates $44.82 million in revenue each year. The biopharmaceutical company earns $-387,470,000.00 in net income (profit) each year or ($8.44) on an earnings per share basis. TESARO employs 446 workers across the globe.

How can I contact TESARO?

TESARO's mailing address is 1000 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 339-970-0900.


MarketBeat Community Rating for TESARO (TSRO)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  433 (Vote Outperform)
Underperform Votes:  247 (Vote Underperform)
Total Votes:  680
MarketBeat's community ratings are surveys of what our community members think about TESARO and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for TESARO (NASDAQ:TSRO)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 9 Hold Ratings, 14 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.61)
Consensus Price Target: $161.00 (91.87% upside)

Consensus Price Target History for TESARO (NASDAQ:TSRO)

Price Target History for TESARO (NASDAQ:TSRO)

Analysts' Ratings History for TESARO (NASDAQ:TSRO)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/20/2017HC WainwrightReiterated RatingBuy$158.00N/AView Rating Details
11/15/2017Leerink SwannUpgradeMarket Perform -> OutperformN/AView Rating Details
11/10/2017SunTrust Banks, Inc.Reiterated RatingBuy$160.00N/AView Rating Details
11/10/2017Robert W. BairdReiterated RatingHold$120.00N/AView Rating Details
11/9/2017Lake Street CapitalReiterated RatingBuy$143.00N/AView Rating Details
11/8/2017Morgan StanleyReiterated RatingOverweight$181.00 -> $165.00N/AView Rating Details
11/7/2017CannReiterated RatingBuy$199.00N/AView Rating Details
11/3/2017Jefferies Group LLCReiterated RatingHold$124.00N/AView Rating Details
10/23/2017Piper Jaffray CompaniesReiterated RatingNeutral -> Neutral$117.00N/AView Rating Details
10/23/2017Barclays PLCInitiated CoverageEqual Weight -> Equal Weight$135.00N/AView Rating Details
9/14/2017Royal Bank Of CanadaInitiated CoverageSector Perform$120.00MediumView Rating Details
9/11/2017WedbushReiterated RatingOutperform$160.00LowView Rating Details
9/10/2017Oppenheimer Holdings, Inc.Reiterated RatingBuy$199.00LowView Rating Details
9/11/2017Citigroup Inc.Reiterated RatingBuy$216.00LowView Rating Details
8/20/2017Wells Fargo & CoReiterated RatingOutperformHighView Rating Details
8/18/2017Credit Suisse GroupSet Price TargetBuy$198.00 -> $190.00HighView Rating Details
8/16/2017Evercore ISIInitiated CoverageIn -> In-Line$121.00HighView Rating Details
7/14/2017Janney Montgomery ScottReiterated RatingNeutralLowView Rating Details
7/7/2017GabelliInitiated CoverageBuy$175.00HighView Rating Details
6/20/2017Raymond James Financial, Inc.Reiterated RatingMarket PerformMediumView Rating Details
6/20/2017Bank of America CorporationReiterated RatingBuy$154.00HighView Rating Details
6/19/2017Cowen IncLower Price TargetMarket Perform$145.00 -> $124.00HighView Rating Details
6/5/2017FBR & CoLower Price TargetMkt Perform -> Mkt Perform$200.00 -> $195.00HighView Rating Details
3/24/2017ArgusInitiated CoverageBuy$210.00HighView Rating Details
8/5/2016MizuhoLower Price TargetBuy$100.00 -> $94.00N/AView Rating Details
(Data available from 11/24/2015 forward)

Earnings

Earnings History and Estimates Chart for TESARO (NASDAQ:TSRO)

Earnings by Quarter for TESARO (NASDAQ:TSRO)

Earnings History by Quarter for TESARO (NASDAQ TSRO)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($1.16)($0.47)$130.57 million$142.77 millionViewN/AView Earnings Details
8/8/2017Q2 2017($2.52)($2.82)$18.61 million$29.50 millionViewListenView Earnings Details
5/9/2017Q1 2017($2.26)($2.55)$3.84 million$3.10 millionViewListenView Earnings Details
11/3/2016Q3($1.92)($1.98)$4.39 million$3.73 millionViewN/AView Earnings Details
5/5/2016Q1($1.69)($2.22)$2.48 million$0.31 millionViewN/AView Earnings Details
2/25/2016Q4($1.63)($1.89)$3.45 million$0.23 millionViewListenView Earnings Details
10/29/2015Q315($1.52)($1.66)$0.09 millionViewListenView Earnings Details
8/6/2015Q215($1.14)($1.51)ViewListenView Earnings Details
4/30/2015Q115($1.12)($1.30)ViewListenView Earnings Details
2/19/2015Q414($1.03)($1.33)ViewListenView Earnings Details
11/5/2014Q314($1.04)($1.01)ViewN/AView Earnings Details
7/24/2014Q214($0.87)($1.03)ViewN/AView Earnings Details
4/30/2014Q114($1.06)($1.43)ViewN/AView Earnings Details
2/19/2014Q413($0.78)($0.72)ViewN/AView Earnings Details
11/7/2013Q313($0.69)($0.88)ViewN/AView Earnings Details
7/25/2013Q2 2013($0.63)($0.67)ViewN/AView Earnings Details
4/25/2013Q1 2013($0.62)($0.66)ViewN/AView Earnings Details
2/14/2013Q4 2012($0.65)($15.41)ViewN/AView Earnings Details
10/25/2012($0.55)($0.52)ViewN/AView Earnings Details
7/26/2012($0.55)($4.11)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for TESARO (NASDAQ:TSRO)
2017 EPS Consensus Estimate: ($8.70)
2018 EPS Consensus Estimate: ($6.49)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20175($2.39)($1.98)($2.20)
Q2 20176($3.10)($2.15)($2.59)
Q3 20176($2.57)($0.52)($1.50)
Q4 20176($2.79)($1.86)($2.41)
Q1 20184($2.17)($1.35)($1.90)
Q2 20184($1.94)($0.93)($1.61)
Q3 20184($1.94)($0.94)($1.56)
Q4 20184($1.76)($1.16)($1.43)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for TESARO (NASDAQ:TSRO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for TESARO (NASDAQ TSRO)

Insider Ownership Percentage: 40.50%
Insider Trades by Quarter for TESARO (NASDAQ:TSRO)
Institutional Ownership by Quarter for TESARO (NASDAQ:TSRO)

Insider Trades by Quarter for TESARO (NASDAQ TSRO)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/22/2017Martin H Jr. HuberSVPSell592$118.60$70,211.20View SEC Filing  
9/18/2017James O ArmitageDirectorSell10,000$117.13$1,171,300.00View SEC Filing  
9/6/2017Edward C EnglishVPSell10,862$134.92$1,465,501.04View SEC Filing  
9/5/2017Orlando OliveiraSVPSell71$132.66$9,418.86View SEC Filing  
9/1/2017Grant C. BogleVPSell14,167$135.00$1,912,545.00View SEC Filing  
6/6/2017Edward C EnglishVPSell8,500$138.65$1,178,525.00View SEC Filing  
4/3/2017Martin H Jr. HuberSVPSell829$153.02$126,853.58View SEC Filing  
3/6/2017Edward C EnglishVPSell10,000$178.06$1,780,600.00View SEC Filing  
3/2/2017Edward C EnglishVPSell229$177.61$40,672.69View SEC Filing  
3/2/2017Grant C. BogleSVPSell1,447$177.61$257,001.67View SEC Filing  
3/2/2017Mary Lynne HedleyCOOSell3,927$177.61$697,474.47View SEC Filing  
1/3/2017Martin H. Jr. HuberSVPSell190$136.26$25,889.40View SEC Filing  
11/2/2016Martin H Jr. HuberSVPSell327$121.29$39,661.83View SEC Filing  
9/22/2016Martin H Jr. HuberSVPSell408$108.12$44,112.96View SEC Filing  
9/8/2016Edward C EnglishVPSell7,000$88.54$619,780.00View SEC Filing  
8/30/2016Jeffrey H HankeVPSell29,166$86.04$2,509,442.64View SEC Filing  
6/30/2016Jeffrey H HankeVPSell12,500$74.35$929,375.00View SEC Filing  
6/10/2016Edward C EnglishVPSell7,000$40.75$285,250.00View SEC Filing  
3/18/2016Arnold L OronskyDirectorBuy142,085$35.19$4,999,971.15View SEC Filing  
3/18/2016Enterprise Associates 13 L NewMajor ShareholderBuy710,429$35.19$24,999,996.51View SEC Filing  
3/10/2016Edward C EnglishVPSell7,000$43.71$305,970.00View SEC Filing  
12/10/2015Edward C. EnglishVPSell17,000$50.19$853,230.00View SEC Filing  
9/8/2015James O ArmitageDirectorBuy500$54.63$27,315.00View SEC Filing  
12/12/2014James O ArmitageDirectorBuy1,000$38.16$38,160.00View SEC Filing  
9/29/2014Lawrence M AllevaDirectorBuy1,100$26.17$28,787.00View SEC Filing  
7/31/2013Lawrence M AllevaDirectorBuy1,449$34.33$49,744.17View SEC Filing  
6/5/2013Peter J BarrisMajor ShareholderSell3,583$39.00$139,737.00View SEC Filing  
4/30/2013Lawrence M AllevaDirectorBuy1,050$28.10$29,505.00View SEC Filing  
11/1/2012Lawrence M AllevaDirectorBuy3,240$15.45$50,058.00View SEC Filing  
8/30/2012Leon O Moulder JrCEOBuy10,000$11.69$116,900.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for TESARO (NASDAQ TSRO)

Source:
DateHeadline
TESARO (TSRO) Ovarian Cancer Drug Zejula Gets Approval in EU - NasdaqTESARO (TSRO) Ovarian Cancer Drug Zejula Gets Approval in EU - Nasdaq
www.nasdaq.com - November 22 at 6:18 PM
TESARO Announces Participation in Two Investor Conferences - GlobeNewswire (press release)TESARO Announces Participation in Two Investor Conferences - GlobeNewswire (press release)
globenewswire.com - November 22 at 6:17 PM
TESARO Announces Participation in Two Investor ConferencesTESARO Announces Participation in Two Investor Conferences
finance.yahoo.com - November 22 at 6:17 PM
TESARO, Inc. (TSRO) Stock Rating Reaffirmed by HC WainwrightTESARO, Inc. (TSRO) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - November 20 at 12:04 PM
TESARO (TSRO) Announce EC Approval of ZEJULA to Treat Ovarian CancerTESARO (TSRO) Announce EC Approval of ZEJULA to Treat Ovarian Cancer
www.streetinsider.com - November 20 at 11:32 AM
TESARO, Inc. (TSRO) Upgraded to Outperform at Leerink SwannTESARO, Inc. (TSRO) Upgraded to Outperform at Leerink Swann
www.americanbankingnews.com - November 19 at 5:38 PM
TESARO, Inc. to Post FY2017 Earnings of ($8.61) Per Share, Leerink Swann Forecasts (TSRO)TESARO, Inc. to Post FY2017 Earnings of ($8.61) Per Share, Leerink Swann Forecasts (TSRO)
www.americanbankingnews.com - November 17 at 7:12 PM
Tesaro Stock Could Have 41% UpsideTesaro Stock Could Have 41% Upside
finance.yahoo.com - November 15 at 5:31 PM
ETFs with exposure to TESARO, Inc. : November 13, 2017ETFs with exposure to TESARO, Inc. : November 13, 2017
finance.yahoo.com - November 14 at 12:09 PM
TESARO, Inc. (TSRO) Receives Consensus Rating of "Hold" from BrokeragesTESARO, Inc. (TSRO) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 13 at 9:34 PM
Equities Analysts Issue Forecasts for TESARO, Inc.s FY2017 Earnings (TSRO)Equities Analysts Issue Forecasts for TESARO, Inc.'s FY2017 Earnings (TSRO)
www.americanbankingnews.com - November 13 at 1:48 AM
TESARO, Inc. (TSRO) Earns Buy Rating from SunTrust Banks, Inc.TESARO, Inc. (TSRO) Earns Buy Rating from SunTrust Banks, Inc.
www.americanbankingnews.com - November 11 at 4:56 PM
TESAROs (TSRO) "Hold" Rating Reaffirmed at Robert W. BairdTESARO's (TSRO) "Hold" Rating Reaffirmed at Robert W. Baird
www.americanbankingnews.com - November 11 at 12:10 PM
FY2017 EPS Estimates for TESARO, Inc. (TSRO) Raised by AnalystFY2017 EPS Estimates for TESARO, Inc. (TSRO) Raised by Analyst
www.americanbankingnews.com - November 10 at 12:41 PM
Gabelli Weighs in on TESARO, Inc.s FY2017 Earnings (TSRO)Gabelli Weighs in on TESARO, Inc.'s FY2017 Earnings (TSRO)
www.americanbankingnews.com - November 10 at 12:40 PM
FY2017 EPS Estimates for TESARO, Inc. (TSRO) Reduced by Leerink SwannFY2017 EPS Estimates for TESARO, Inc. (TSRO) Reduced by Leerink Swann
www.americanbankingnews.com - November 10 at 12:40 PM
FY2017 EPS Estimates for TESARO, Inc. Lifted by Analyst (TSRO)FY2017 EPS Estimates for TESARO, Inc. Lifted by Analyst (TSRO)
www.americanbankingnews.com - November 10 at 12:40 PM
TESARO, Inc. (TSRO) to Post FY2017 Earnings of ($8.20) Per Share, Jefferies Group ForecastsTESARO, Inc. (TSRO) to Post FY2017 Earnings of ($8.20) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - November 10 at 12:40 PM
FY2020 Earnings Forecast for TESARO, Inc. (TSRO) Issued By Jefferies GroupFY2020 Earnings Forecast for TESARO, Inc. (TSRO) Issued By Jefferies Group
www.americanbankingnews.com - November 9 at 4:02 PM
Lake Street Capital Reaffirms "Buy" Rating for TESARO, Inc. (TSRO)Lake Street Capital Reaffirms "Buy" Rating for TESARO, Inc. (TSRO)
www.americanbankingnews.com - November 9 at 3:42 PM
FY2019 Earnings Forecast for TESARO, Inc. (TSRO) Issued By Oppenheimer HoldingsFY2019 Earnings Forecast for TESARO, Inc. (TSRO) Issued By Oppenheimer Holdings
www.americanbankingnews.com - November 9 at 3:40 PM
 Analysts Anticipate TESARO, Inc. (TSRO) Will Post Earnings of -$2.31 Per Share Analysts Anticipate TESARO, Inc. (TSRO) Will Post Earnings of -$2.31 Per Share
www.americanbankingnews.com - November 9 at 11:40 AM
TESARO, Inc. (TSRO) Forecasted to Post Q1 2018 Earnings of ($2.11) Per ShareTESARO, Inc. (TSRO) Forecasted to Post Q1 2018 Earnings of ($2.11) Per Share
www.americanbankingnews.com - November 9 at 11:12 AM
TESARO Announces Third-Quarter 2017 Operating Results - GlobeNewswire (press release)TESARO Announces Third-Quarter 2017 Operating Results - GlobeNewswire (press release)
globenewswire.com - November 9 at 8:41 AM
Earnings Reaction History: TESARO, Inc., 66.7% Follow-Through Indicator, 5.1% Sensitive - NasdaqEarnings Reaction History: TESARO, Inc., 66.7% Follow-Through Indicator, 5.1% Sensitive - Nasdaq
www.nasdaq.com - November 9 at 8:41 AM
TESARO, Inc. (TSRO) Earns Buy Rating from HC WainwrightTESARO, Inc. (TSRO) Earns Buy Rating from HC Wainwright
www.americanbankingnews.com - November 8 at 10:26 PM
TESARO, Inc. (TSRO) Releases Quarterly  Earnings Results, Beats Expectations By $0.69 EPSTESARO, Inc. (TSRO) Releases Quarterly Earnings Results, Beats Expectations By $0.69 EPS
www.americanbankingnews.com - November 8 at 3:02 PM
TESARO, Inc. (TSRO) Price Target Cut to $165.00TESARO, Inc. (TSRO) Price Target Cut to $165.00
www.americanbankingnews.com - November 8 at 11:13 AM
TESARO, Inc. (TSRO) Given Buy Rating at CannTESARO, Inc. (TSRO) Given Buy Rating at Cann
www.americanbankingnews.com - November 7 at 11:51 PM
Tesaro reports 3Q lossTesaro reports 3Q loss
finance.yahoo.com - November 7 at 8:46 PM
TESARO, Inc. (TSRO) Rating Reiterated by Jefferies Group LLCTESARO, Inc. (TSRO) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - November 5 at 4:56 PM
TESARO, Inc. (TSRO) Expected to Earn FY2021 Earnings of $14.60 Per ShareTESARO, Inc. (TSRO) Expected to Earn FY2021 Earnings of $14.60 Per Share
www.americanbankingnews.com - October 30 at 11:53 AM
OncoQuest Announces Collaboration with TESARO in Recurrent Ovarian Cancer SettingOncoQuest Announces Collaboration with TESARO in Recurrent Ovarian Cancer Setting
www.bizjournals.com - October 27 at 7:07 AM
OPKO Health (OPK) Licensee TESARO (TSRO) Granted FDA Approval of VARUBIOPKO Health (OPK) Licensee TESARO (TSRO) Granted FDA Approval of VARUBI
www.streetinsider.com - October 27 at 7:07 AM
TESARO, Inc. (TSRO) Rating Reiterated by HC WainwrightTESARO, Inc. (TSRO) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - October 26 at 5:24 PM
TESARO (TSRO) Announces FDA Approval of VARUBI for Delayed Nausea and Vomiting Associated ChemoTESARO (TSRO) Announces FDA Approval of VARUBI for Delayed Nausea and Vomiting Associated Chemo
www.streetinsider.com - October 26 at 12:50 PM
Tesaro Shares Move Higher On Latest FDA Approval; Analyst Is Highly EncouragedTesaro Shares Move Higher On Latest FDA Approval; Analyst Is 'Highly Encouraged'
finance.yahoo.com - October 26 at 12:50 PM
OPKO Health Licensee TESARO Announces FDA Approval of VARUBI® IV for Delayed Nausea and Vomiting Associated with ChemotherapyOPKO Health Licensee TESARO Announces FDA Approval of VARUBI® IV for Delayed Nausea and Vomiting Associated with Chemotherapy
finance.yahoo.com - October 26 at 12:50 PM
TESARO Announces US FDA Approval of VARUBI® IV for Delayed Nausea and Vomiting Associated With Cancer ... - GlobeNewswire (press release)TESARO Announces US FDA Approval of VARUBI® IV for Delayed Nausea and Vomiting Associated With Cancer ... - GlobeNewswire (press release)
globenewswire.com - October 25 at 8:28 PM
TESARO, Inc. (TSRO) Scheduled to Post Quarterly Earnings on WednesdayTESARO, Inc. (TSRO) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - October 25 at 8:36 AM
TESARO Announces Participation at Two Investor Conferences - GlobeNewswire (press release)TESARO Announces Participation at Two Investor Conferences - GlobeNewswire (press release)
globenewswire.com - October 23 at 8:32 PM
$121.33 Million in Sales Expected for TESARO, Inc. (TSRO) This Quarter$121.33 Million in Sales Expected for TESARO, Inc. (TSRO) This Quarter
www.americanbankingnews.com - October 22 at 5:28 AM
Zacks: Analysts Anticipate TESARO, Inc. (TSRO) to Announce -$1.09 EPSZacks: Analysts Anticipate TESARO, Inc. (TSRO) to Announce -$1.09 EPS
www.americanbankingnews.com - October 20 at 4:24 PM
The Foundation for Womens Cancer and TESARO Announce 2nd Year of Partnership Supporting the National Race to ... - GlobeNewswire (press release)The Foundation for Women's Cancer and TESARO Announce 2nd Year of Partnership Supporting the National Race to ... - GlobeNewswire (press release)
globenewswire.com - October 20 at 9:27 AM
TESARO, Inc. (TSRO) Given Consensus Recommendation of "Hold" by BrokeragesTESARO, Inc. (TSRO) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - October 19 at 8:46 PM
AstraZenecas sNDA for Two Cancer Drugs Gets Priority ReviewAstraZeneca's sNDA for Two Cancer Drugs Gets Priority Review
finance.yahoo.com - October 19 at 10:07 AM
TESARO, Inc. (TSRO) Receives New Coverage from Analysts at HC WainwrightTESARO, Inc. (TSRO) Receives New Coverage from Analysts at HC Wainwright
www.americanbankingnews.com - October 15 at 7:56 AM
TESARO, Inc. (TSRO) Short Interest UpdateTESARO, Inc. (TSRO) Short Interest Update
www.americanbankingnews.com - October 13 at 1:58 AM
The Zacks Analyst Blog Highlights: Flexion Therapeutics, Alexion Pharmaceuticals, PTC Therapeutics, Johnson & Johnson and TESAROThe Zacks Analyst Blog Highlights: Flexion Therapeutics, Alexion Pharmaceuticals, PTC Therapeutics, Johnson & Johnson and TESARO
finance.yahoo.com - October 6 at 11:51 AM
Are Options Traders Betting on a Big Move in Tesaro (TSRO) Stock?Are Options Traders Betting on a Big Move in Tesaro (TSRO) Stock?
finance.yahoo.com - October 6 at 11:51 AM

Social Media

Financials

Chart

TESARO (NASDAQ TSRO) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.